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Diminished quality of life (QOL) is a common feature of epilepsy. It is generally more severe among patients with poor seizure
control but prevalent, to a clinically significant degree, even among those whose seizures are well controlled. People with
epilepsy frequently report diminished socialization, negative self image, feelings of stigmatization, reduced earnings potential,
and diminished hope and ambition. Problems with antiepileptic drug (AED) therapy are common, and AED therapy is recog-
nized as an important determinant of health-related quality of life (HRQOL). A clinically efficient psychometric instrument is
needed to measure its impact. The Side Effect and Life Satisfaction (SEALS) inventory is a 38-item, patient-completed question-
naire designed to measure satisfaction with AED therapy. We tested its construct validity in comparison with three widely used
psychometric instruments of similar design, the Profile of Mood States (POMS), the Hospital Anxiety and Depression (HAD)
scale, and the Medical Outcomes Study-Cognitive Functioning (MOS-COG) scale.
All four instruments were completed by 307 epilepsy patients. A matrix of Pearson’s correlations was produced for the
SEALS inventory and the comparative instruments. A statistically significant correlation was found for each planned compari-
son. We conclude that the SEALS inventory is a valid psychometric instrument, well suited for use in clinical investigations of
AED therapy and in the practical, long-term management of epilepsy.
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INTRODUCTION
There is ample evidence that many people with
epilepsy also suffer a clinically significant deficit in
health-related quality of life (HRQOL)1–3, both in
terms of symptoms resulting directly from the con-
dition, and loss of psychosocial functioning conse-
quent upon these symptoms. The psychosocial in-
jury of epilepsy is more severe among patients with
poor seizure control, but prevalent, to a clinically sig-
nificant degree, even among patients whose seizures
are reasonably well controlled1, 2. Baker et al.1 sur-
veyed 5211 members of epilepsy support groups and
outpatient clinics in 15 European countries—a study
population acknowledged to contain a disproportion-
ately high number of people with epilepsy of greater
than average severity. Many respondents said epilepsy
had negatively affected their plans and ambitions
(47%), social life (41%), and feelings about them-
selves (40%). Thirty-eight percent said epilepsy had
diminished their ability to work and their standard of
living. In a smaller survey2 of 696 patients selected by
protocol (≥1 seizure in the past 2 years or seizure-free
on continuing AED therapy) from the records of 31
UK general practitioners, 44% of patients answered ‘a
lot’ or ‘some’ when asked if epilepsy had limited the
kind of work they could do. Other aspects of life re-
ported to be similarly affected included relationships
with friends (37%), feelings of self (37%), plans and
ambitions (35%), social activities (32%), and ability to
work (29%).
Aside from its anticonvulsant effects, AED therapy
is an important medical factor influencing HRQOL.
Not only is drug therapy a daily reminder to the patient
of his or her condition, it can also exert a strong neg-
ative influence in the form of unwanted side effects,
particularly cognitive and neurological impairment4.
Baker et al.1 reported that 88% of 96% of 5211 re-
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spondents on AEDs experienced at least one neuro-
logical AED side effect in the month prior to the sur-
vey. The most common were tiredness (58%), mem-
ory problems (50%), difficulty concentrating (48%),
sleepiness (45%), difficulty thinking clearly (40%),
and nervousness and agitation (36%). Forty-four per-
cent said they worried ‘a lot’ or ‘some’ about the
possible side effects of AED therapy, and 31% had
changed AEDs at least once in the past year because of
side effects. Patients in the UK-generalists study2 re-
ported AED side effects ‘always a problem’ or ‘some-
times a problem’ as follows: tiredness (41%), mem-
ory problems (33%), difficulty concentrating (30%),
sleepiness (28%), nervousness/agitation and headache
(26%, each), depression (25%), disturbed sleep (24%),
restlessness (21%), and feelings of aggression (19%).
To better understand the component role of AED
therapy in HRQOL and to determine whether the
psychosocial injury of epilepsy can be ameliorated
without compromising the primary therapeutic goal of
optimum seizure control, researchers and practitioners
need a reliable, validated, clinically efficient psycho-
metric instrument to measure patient satisfaction with
AED therapy. In 1982, Brown and Tomlinson5 de-
scribed the development of a patient-completed ques-
tionnaire to assess the psychosocial effects of AED
therapy, termed the Side Effect and Life Satisfac-
tion (SEALS) inventory, using a patient population
to generate key symptoms. The goal was to construct
an instrument to distinguish not just drug effects from
disease effects, but also to distinguish the psychoso-
cial effects of one antiepileptic drug from those of
another in comparative clinical trials. To be useful in
such studies, the questionnaire had to be practical for
repeated use, i.e. simple to understand and not exces-
sively time consuming. It also had to be sensitive to
small changes in the patient’s HRQOL over time. The
final version comprised 50 questions scored on a four-
point Likert scale and grouped by five subscales or
‘factors’: fatigue; satisfaction; interpersonal relations;
mood and irritability; and general cognitive difficul-
ties.
Gillham et al.6 studied and modified the Brown–
Tomlinson SEALS to produce the refining of the five
factors and reducing the number of questions to 38,
using principal components analysis. The twelve dis-
carded questions did not load significantly on any one
factor; they tended to be items confounded by fac-
tors not necessarily related to the patient’s epilepsy,
such as marital status, or personal preferences. Gill-
ham and associates also showed that the five SEALS
factors were sensitive to differences between treatment
groups and to changes in treatment, findings that sug-
gest the SEALS inventory would be useful to assess
patient satisfaction with anticonvulsant therapy.
The present study was undertaken to test the con-
struct validity of the SEALS inventory, using for com-
parison three well-validated instruments similar to the
SEALS inventory or one of its five factors: the Profile
of Mood States (POMS)7, the Hospital Anxiety and
Depression (HAD) scale8, and the Medical Outcomes
Study-Cognitive Functioning (MOS-COG) scale9.
MATERIALS AND METHODS
Approval from the local Ethics Committee was sought
and obtained at two sites; (Glasgow and Dundee),
at the third, (Liverpool), completion of the question-
naires was deemed a normal part of clinical practice,
obviating Committee approval.
Patients and data collection
Enrollment was open to men and women 18 years of
age or older with epilepsy diagnosed by a consultant
neurologist. Newly diagnosed patients and patients
still undergoing investigation were excluded, as were
those who lacked the ability to read, comprehend,
and complete the SEALS inventory and comparative
instruments without assistance (12 patients). Demo-
graphic data and information on disease characteris-
tics were gathered by clinic personnel through direct
interview and from clinic records.
Consecutively presenting patients at three clinics
were invited to participate in the study. Each prospec-
tive patient received written and oral instruction re-
garding the nature and purpose of the study. Consent
was inferred from the informed patient’s willingness
to participate, and was virtually 100% amongst those
patients who did not have further appointments im-
posing time constraints. Refusal to participate in one
centre (Liverpool n = 100) was not recorded, but
in the other two centres was less than 1%. Partici-
pation entailed completing the SEALS inventory and
the three comparative instruments. Written and oral in-
structions for each instrument were provided, but once
the patient began, no further assistance was available
except staff’s encouragement to carefully reread the
written instructions. Questionnaires were completed in
the clinic, in a side room, before the patient’s routine
appointment. There was no time limit, implied or pre-
scribed, for completion of the SEALS inventory or the
other instruments, and the average time to complete
was 45 minutes.
Psychometric instruments and validation
strategy
The SEALS inventory contains 38 questions related
to the patient’s feelings and behaviour over the past
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week, e.g. ‘Have you felt enthusiastic about doing
things?’ ‘Have you been irritable with people?’. The
questions are grouped into five subscales based on the
results of factor analysis, termed: Worry, Temper, Cog-
nition, Dysphoria, and Tiredness. Each question is an-
swered on a four-point Likert scale (0= never, 1= oc-
casionally, 2= sometimes, 3=many times). Answers
are summed to provide a score for each factor, and fac-
tor scores are totaled for an overall SEALS score.
Table 1: Validation strategy for the SEALSa inventory and its
five factors.
SEALS component Comparative instrument (or subscale)
SEALS inventory (total) HAD scale (total)
1. Worry HAD anxiety subscale
2. Temper POMS anger and hostility subscale
3. Cognition MOS-COG scale
4. Dysphoria POMS vigour-activity subscale and
HAD depression subscale
5. Tiredness POMS fatigue subscale
a Abbreviations: SEALS = Side Effect and Life Satisfaction; HAD
= Hospital Anxiety and Depression; POMS = Profile of Mood
States; MOS-COG =Medical Outcomes Study-Cognitive
Functioning.
The POMS scale7 measures six mood states:
tension-anxiety, depression-rejection, anger-hostility,
vigour-activity, fatigue-inertia, and confusion-
bewilderment. Sixty-five adjectives (e.g. tense, lively,
nervous, worthless) are rated on a five-point Likert
scale (0 = not at all, 1 = a little, 2 = moderately, 3 =
quite a bit, 4 = extremely). Patients are asked to relate
each adjective to their personal sense of well-being
over the past week.
The HAD scale8 consists of two subscales (depres-
sion and anxiety) comprising 14 statements about the
patient’s feelings over the past week, e.g. ‘I feel tense
or wound up.’ Patients choose one of four possible
responses to which point values have been assigned,
e.g. ‘not at all’ (no points), ‘occasionally’ (1 point), ‘a
lot of the time’ (2 points), and ‘most of the time’ (3
points). Items are summed by subscale to provide two
scores: one for depression and one for anxiety.
The MOS-COG scale9 uses six questions scored on
a six-point Likert scale to provide a general measure of
the patient’s cognitive function from his or her point
of view, e.g. ‘Did you have difficulty reasoning and
solving problems, for example, making plans, making
decisions, learning new things?’ (1 = all of the time,
2 = most of the time, 3 = a good bit of the time, 4
= some of the time, 5 = a little of the time, and 6 =
none of the time). Answers are summed to provide a
single score reflecting such concepts as confusion, for-
getfulness, slowed reaction, difficulty reasoning, trou-
ble paying attention, and difficulty with activities that
require mental concentration.
Total SEALS score was validated against total
POMS score. The validation strategy for individual
factor scores is shown in Table 1.
RESULTS
Three hundred and seven volunteers contributed us-
able data to this study. Table 2 summarizes their de-
mographic and disease characteristics. Questionnaires
with less than 80% of the items answered according
to the protocol were not used in the final analysis, and
data from 15 patients were thus excluded, for a com-
pliance rate of 95% (307/322).
A matrix of Pearson’s correlations was produced
for the SEALS inventory and the comparative in-
struments. Correlations between measures had to be
greater than 0.3 to be considered evidence of the con-
vergent validity of the SEALS inventory. A statisti-
cally significant correlation was found for each com-
parison (Table 3).
DISCUSSION
The SEALS inventory was originally designed to mea-
sure the effects of anticonvulsant therapy on psychoso-
cial functioning. Detailed accounts of the method by
which it was developed are given in Brown and Tom-
linson5 and Gillham et al.6, and will not be reiterated
here. The earliest unpublished versions may be con-
sidered somewhat diffuse, with some degree of arbi-
trariness in item selection, but subsequent studies5, 6
have refined it and in its present form, the SEALS in-
ventory demonstrates the requisite qualities of validity,
reliability, and responsiveness to be useful in clinical
research and in the practical setting. Kane et al.10 used
data from three clinical trials of lamotrigine (n = 380)
to evaluate the reliability of the SEALS inventory.
Scale structure was evaluated across each study by
calculating item-scale correlations for each item, us-
ing Cronbach’s coefficient alpha. Internal consistency
was also measured using Cronbach’s coefficient alpha;
a value greater than 0.7 is considered sufficient evi-
dence of internal consistency11. Ninety-one percent of
the correlations (104 of 114) matched their expected
subscale, and Cronbach’s alpha was >0.7 for the tem-
per, cognition, dysphoria, and tiredness subscales. For
the worry subscale, internal consistency varied from
0.65 to 0.70, depending on the study.
Responsiveness of the SEALS inventory has been
demonstrated in three clinical studies comparing lam-
otrigine (LTG) with carbamazepine (CBZ), pheny-
toin (PHT), and valproate (VPA). The SEALS in-
ventory was used in each study to monitor drug ef-
fects on HRQOL. In a 48-week randomized, double-
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Table 2: Patient demographics and disease characteristics.
n(%) Mean (SD) Range
Patients 307
Male 134 (43.6)
Female 171 (55.7)
Data unavailable 2 (0.7)
Age (years) 303a 37.82 (12.4) 18–71
Age at onset of seizures (years) 300a 19.53 (14.3) 0–62
Years since onset of seizures 298a 18.29 (12.1) 0–52
Number of seizures in past 3 months 261a 25.34 (90.1) 0–1000
Other significant neurological disorderb
Yes 25 (8.1)
No 274 (89.3)
Data unavailable 8 (2.6)
Seizure type
Complex partial 88 (28.7)
Tonic–clonic 67 (21.8)
Absence 49 (16.0)
Simple partial 42 (13.7)
Secondary generalized 31 (10.1)
Myoclonic 5 (1.6)
Tonic 5 (1.6)
Data unavailable 20 (6.5)
Anticonvulsant therapy
Carbamazepine 72 (23.5)
Valproate 33 (10.7)
Phenytoin 13 (4.2)
Lamotrigine 12 (3.9)
Other monotherapy 22 (7.2)
Carbamazepine + lamotrigine 22 (7.2)
Other carbamazepine polytherapy 60 (19.5)
Other lamotrigine polytherapy 29 (9.4)
Other polytherapy 24 (7.8)
None 6 (2.0)
Data unavailable 14 (4.6)
a Data unavailable for some patients.
b As evaluated by clinic personnel.
Table 3: Correlations: SEALSa inventory and comparative instruments.
SEALS Inventory Instrument/Subscale Correlationb Significance
TOTAL POMSa (total score) 0.8002 P < 0.000
Cognition MOS-COGa (total score) 0.8441 P < 0.000
Dysphoria POMS/vigour 0.5133 P < 0.000
HAD/depression 0.5883 P < 0.000
Tiredness POMS/fatigue 0.5863 P < 0.000
Temper POMS/anger-hostility 0.6290 P < 0.000
Worry HAD/anxiety 0.5306 P < 0.000
a Abbreviations: SEALS = Side Effect and Life Satisfaction inventory; POMS = Profile of Mood States; MOS-COG =Medical Outcomes
Study Cognitive scale; HAD = Hospital Anxiety and Depression scale.
b Correlation between measures had to be ≥0.3 to be considered evidence of the convergent validity of the SEALS inventory.
blind comparison of LTG and CBZ12, SEALS scores
showed significant improvement from baseline among
LTG patients. The CBZ group showed no improve-
ment. This finding is consistent with the LTG group’s
higher 48-week completion rate of 65% vs. 51%. In
a 48-week randomized, double-blind comparison of
LTG and PHT13, SEALS scores improved in the LTG
group but worsened slightly in the PHT group; the fi-
nal difference was statistically significant, again mir-
roring a higher study completion rate among the LTG
patients. In an interim analysis of a 28-week random-
ized, open-label crossover study of LTG and VPA14,
SEALS scores improved 28% in the LTG group, com-
pared with 11% in the VPA group. The estimated dif-
ferences between treatments (LTG and VPA) at weeks
12 and 28 were −4.99 (95% Cl −10.32, 0.34) and
−8.87 (95% Cl −15.32, −2.42), respectively.
Culturally validated translations of the SEALS in-
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ventory have recently been completed, expanding
its utility for international and multinational studies.
Mear et al.15 have described the process by which the
SEALS inventory was translated from UK English to
nine other languages: Dutch, Danish, French, German,
Italian, Spanish, Swedish, US English, and Canadian
French. For each language, two independent transla-
tions of the SEALS inventory were completed by na-
tive speakers of the target language who were also flu-
ent in the source language (UK English). Those ‘for-
ward’ translations were reconciled into a single ver-
sion and then translated back into UK English by a
native speaker of UK English who was fluent in the
target language. The ‘back’ translation was then com-
pared and reconciled with the original SEALS inven-
tory. For each target language, five native speakers
with epilepsy were enlisted to test the clarity, appro-
priateness, and acceptability of the translated SEALS
inventory, and at an international harmonization meet-
ing, the nine translations were compared with each
other and with the original to ensure the conceptual
equivalence of all versions.
Missing data are the bane of quality-of-life research,
and we are pleased to note that 95% of the patients in
the present study returned questionnaires with ≥80%
of the requested information supplied, with less than
1% refusing to participate in the two centres where
such data was recorded. The situation in which the
questionnaires were completed, in a clinic, with per-
sonnel known to the patient making the request, may
have somewhat artificially raised compliance rate. The
relatively short length of 38 questions and simple
design of the SEALS inventory, however, probably
confers an advantage of simplicity over instruments
such as like the Liverpool HRQOL Battery16, the
Epilepsy Surgery Inventory17, and QOLIE-8918 in that
the SEALS response choices are uniform throughout
the inventory and each item is graded on the same four-
point Likert scale.
The sample used for the study is highly selected. All
patients were attending tertiary centres, and so there
was a bias towards patients with poor seizure control.
Those with learning disability were not able to take
part if the demands of completing the questionnaires
were beyond them. Thus, two very significant groups
amongst people with epilepsy, those with good seizure
control, and those with learning disability, were un-
derrepresented. If the purpose of the study had been
to draw any conclusions about epilepsy or its treat-
ment, then clearly there would be a major flaw in the
methodology, but since the purpose was to validate the
SEALS against other measures, the selection bias is
of less significance. There is a theoretical possibility
that at the lower ends of scoring (better HRQOL), not
well represented in this sample, the correlations be-
tween the instruments would be different; it might be
supposed that they would be less because patient re-
sponses might be more influenced by non-illness re-
lated factors, and therefore subject to greater individ-
ual differences. If the intention was to use the SEALS
amongst a population of non-clinic attenders, presum-
ably bettered controlled with fewer AED side effects,
then a further validation study with a sample from
that population might be desirable. It is envisaged,
however, that the SEALS should be used to monitor
patients attending the same kind of clinics as those in
this study, where HRQOL is a major issue. It is most
important, therefore, that the instrument should be val-
idated in that population.
CONCLUSION
The present study affirms the construct validity of the
SEALS inventory, giving researchers and practition-
ers an effective and efficient tool to study and monitor
the effect of AED therapy on HRQOL. The SEALS
inventory is easy to administer and easy to complete.
Clinical studies prove it is sensitive to small changes
in HRQOL and can distinguish between different anti-
convulsant drugs. The recent completion of nine cross-
cultural translations from the UK English original
increases the potential usefulness of the SEALS in
multinational trials of AED therapy as well as the day-
to-day management of epilepsy around the world.
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